Sayna Norouzi is a Nephrology physician affiliated with Loma Linda University Medical Center. OpenAlex indexes 125 publications with 464 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11234 Anderson St # Mc1516
Loma Linda, CA 923542804
Telephone
909-558-4499Provider last certified this registry record 2 Nov 2021.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202517 payments$40,972openpaymentsdata.cms.gov ↗
- Calliditas Therapeutics US Inc.Program year202528 payments$34,923openpaymentsdata.cms.gov ↗
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year202512 payments$26,987openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.7%Loop diuretic14.4%Furosemide79%Bumetanide21%Part D<11 patientsAngiotensin receptor blocker (ARB)11.7%Losartan Potassium100%Part D≥13 patients+ 5 more classes in this area
Metabolism & gastrointestinal
22.7%Corticosteroid13%Prednisone100%Part D<11 patientsSGLT2 inhibitor9.6%Jardiance71%Farxiga29%Part D<11 patientsCancer & immunology
13.3%Calcineurin inhibitor8.2%Tacrolimus58%Lupkynis42%Part D<11 patientsB Lymphocyte Stimulator-specific Inhibitor5%Benlysta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Infection to hypertension: a review of post-COVID-19 new-onset hypertension prevalence and potential underlying mechanisms
Frontiers in Cardiovascular Medicine
2025 - Patient-physician communication in advanced kidney disease: a narrative review
Journal of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jalaj Garg, MD
Loma Linda University Medical Center
Alan Jacobson, MD
Loma Linda University Medical Center
Subhas Gupta, MD
Loma Linda University Medical Center
Josef Ludwig
Loma Linda University Medical Center
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”